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ABSTRACT
C3 glomerulopathy refers to a disease process in which abnor-
mal control of complement activation, degradation or depos-
ition results in predominant C3 fragment deposition within
the glomerulus and glomerular damage. Recent studies have
improved our understanding of its pathogenesis. The key ab-
normality is uncontrolled C3b ampliﬁcation in the circulation
and/or along the glomerular basement membrane. Family
studies in which disease segregates with structurally abnormal
complement factor H-related (CFHR) proteins demonstrate
that abnormal CFHR proteins are important in some types of
C3 glomerulopathy. This is currently thought to be due to the
ability of these proteins to antagonize the major negative regu-
lator of C3 activation, complement factor H (CFH), a process
termed ‘CFH de-regulation’. Recent clinicopathological cohort
studies have led to further reﬁnements in case deﬁnition, cul-
minating in a 2013 consensus report, which provides recom-
mendations regarding investigation and treatment. Early
clinical experience with complement-targeted therapeutics,
notably C5 inhibitors, has also now been published. Here, we
summarize the latest developments in C3 glomerulopathy.
Keywords: C3 glomerulopathy, complement, dense deposit,
factor H
INTRODUCTION
C3 glomerulopathy designates ‘a disease process due to abnor-
mal control of complement activation, deposition, or degrad-
ation and characterized by predominant glomerular C3
fragment deposition with electron-dense deposits on electron
microscopy’ [1]. It often progresses to end-stage kidney
disease (ESKD) and recurs after renal transplantation. The
prototypical form of C3 glomerulopathy is dense deposit
disease (DDD), which historically has been diagnosed based
on linear, hyperosmiophilic electron-dense deposits occupying
the middle layer of the glomerular basement membrane
(GBM). ‘C3 glomerulonephritis’ (C3GN) refers to those cases
of C3 glomerulopathy in which the electron-dense deposits do
not have this classic appearance.
One striking observation in patients with C3 glomerulopa-
thy is how commonly clinical presentation is preceded by an
infectious episode. This suggests that infection may initiate or
exacerbate the disease process, for example by acting as an ex-
ogenous trigger of C3 activation. Once C3 is activated, abnor-
mal glomerular accumulation of C3 fragments occurs due to
uncontrolled C3b ampliﬁcation via the alternative pathway
(AP). In the majority of patients with C3 glomerulopathy, ac-
quired or genetic defects in AP regulation can be demon-
strated. In 2013, a consensus report in C3 glomerulopathy was
published with recommendations regarding case deﬁnition,
investigation and treatment [1]. At present, all patients in
whom C3 glomerulopathy is diagnosed on either native or
transplant kidney biopsy should be investigated for low plasma
levels of C3, C4 and complement factor H (CFH), and the
presence of paraprotein (i.e. monoclonal gammopathy), C3
nephritic factor and abnormal complement factor H-related
protein 5 (CFHR5).
CFH is the main plasma regulator of the AP and consists of
20 protein subunits, termed short consensus repeat (SCR)
domains, that are encoded within the regulators of comple-
ment (RCA) gene cluster on chromosome 1q32. The CFH–
CFHR protein family (Figure 1A) comprises CFH and ﬁve
structurally related CFHR proteins that are encoded down-
stream of the CFH gene. Frequent interspersed repeat elements
across the CFH–CFHR locus predispose to genomic© The Author 2014. Published by Oxford University Press on behalf of ERA-
EDTA. This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License (http://creativecommons.org/
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rearrangements, a number of which are associated with the
renal pathologies atypical haemolytic uraemic syndrome
(aHUS) and C3 glomerulopathy. CFH surface recognition
domains at the carboxy (C)-terminus contain ligand-binding
sites for glycosaminoglycans and C3b and are highly con-
served on CFHR proteins. In contrast, the ﬁrst four amino
(N)-terminal SCR domains of CFH, which confer its comple-
ment regulatory functions, are absent from the CFHR pro-
teins. As a consequence, CFHR proteins do not possess the
physiological CFH regulatory activity mediated by these SCR
domains. Distinct N-terminal SCR domains 1 and 2 are highly
conserved on CFHR1, CFHR2 and CFHR5 (Figure 1B), and
these are important in dimerization.
RECENT FAMILY STUDIES
In 2010, Gale et al. demonstrated segregation of C3GN with a
heterozygous mutation of CFHR5 involving internal duplica-
tion of exons 2 and 3 (which encode N-terminal SCR domains
1 and 2, respectively) in a large Greek Cypriot cohort [2].
Since the original description of Cypriot ‘CFHR5 nephropa-
thy’, a number of families with autosomal dominant C3GN
and distinct CFHR mutations have been reported. A striking
common feature has been internal duplication of exons or for-
mation of hybrid genes resulting in abnormal CFHR proteins
with duplication of N-terminal SCR domains 1 and 2
(Figure 2). Recent family studies in C3 glomerulopathy and
membranoproliferative glomerulonephritis (MPGN) are
brieﬂy summarized below (see also Table 1), followed by a dis-
cussion of the pathophysiological implications of abnormal
CFHR proteins.
Medjeral-Thomas et al. demonstrated segregation of a het-
erozygous mutation in CFHR5 that results in duplication of
SCR domains 1 and 2 with C3GN in a family without Cypriot
ancestry [6]. Although the abnormal protein, CFHR5121–9, is
identical to that reported in Cypriot CFHR5 nephropathy, the
respective genomic breakpoints within CFHR5 intron 3 are
distinct. It is now recommended that assays to screen for the
presence of CFHR5121–9 are performed in patients with C3
glomerulopathy irrespective of ancestry.
Malik et al. identiﬁed a novel heterozygous CFHR mutation
in a large, Irish kindred in which C3GN had previously been
linked to the RCA gene cluster [3]. Deletion of a genomic
segment comprising exons 4–6 of CFHR3 and exon 1 of
CFHR1 produced a hybrid protein in which SCR domains 1
and 2 of CFHR3 are linked to full-length CFHR1. The hybrid
CFHR312–CFHR1 gene was located on an allele also bearing
intact CFHR1 and CFHR3 genes, suggesting disease causation
due to a gain of function.
Tortajada et al. reported a Spanish family with C3 glomeru-
lopathy and a heterozygous mutation resulting in an abnormal
CFHR1 protein with duplication of SCR domains 1–4 [5].
F IGURE 1 : The CFH–CFHR protein family. (A) CFH consists of 20 SCR domains. Those at the C-terminus (depicted in yellow) mediate
surface recognition and are common to the ﬁve CFHR proteins (CFHR4 has two isoforms, CFHR4A and CFHR4B). In contrast, N-terminal
SCR domains mediating CFH complement regulatory function (red) are not found on CFHR proteins. The N-terminal SCR domains 1 and 2
are highly conserved on CFHR1, CFHR2 and CFHR5 (blue) but not CFHR3 and CFHR4A/B, with very high sequence homology (B).
F IGURE 2 : Family studies have identiﬁed abnormal CFHR
proteins associated with C3 glomerulopathy. These include duplica-
tion of N-terminal SCR domains and formation of a hybrid CFHR
protein containing two domains from CFHR3 (depicted in purple)
linked to the whole of CFHR1.
F
U
L
L
R
E
V
IE
W
2 T.D. Barbour et al.
 at Im
perial C
ollege L
ondon on N
ovem
ber 10, 2015
http://ndt.oxfordjournals.org/
D
ow
nloaded from
 
Table 1. Recent family studies in C3 glomerulopathy and MPGN
Original
report (year)
Reported diagnosis Affected member
(Case number)
Glomerular IF/IHC EM deposits C3
levels
C3NeF CFH
levels
Modiﬁed CFHR
proteins
Molecular defect(s)
Gale et al.
(2010) [2]
(Cypriot) CFHR5
nephropathy
Mother
(Family 1 IV-5)
Son (Family 1 V-4)
Great uncle
(Family 1 II.1)
Aunt (Family 1 IV.1)
Uncle (Family 2 III.2)
C3 pos; C1q/C4/Ig
neg
Subendothelial,
mesangial >
subepithelial
Normal Neg Normal CFHR5121–9 Heterozygous internal duplication of
exons 2–3 (SCRs1–2) in CFHR5
Malik et al.
(2012) [3]/
Neary (2002)
C3GN Father (105) C3 pos; Ig neg Subendothelial, IM,
subepithelial, mesangial
Normal Neg Normal Hybrid
CFHR312–CFHR1
(in addition to
CFHR1, 3)
Heterozygous hybrid gene with deletion
of exons 4–6 (SCRs 3–5) of CFHR3 and
exon 1 of CFHR1 (in addition to normal
CFHR3/1 genes)
Elder son (212)
Younger son (213)
Subendothelial, IM,
subepithelial
Low–
normal
Daughter (214) Normal
Paternal aunt (103) — —
Paternal aunt’s daughter (223) — Subendothelial,
subepithelial, mesangial
— — —
Ozaltin et al.
(2013) [4]
Glomerular
microangiopathy with
histologic signs of both
MPGN and endothelial
distress
Brother (Family
UT-062 V-2)
— — Normal — — — Homozygous DGKE c.127C>T (p.Q43X)
Brother (Family
UT-062 V-3)
C3 pos Subendothelial
Brother (Family
UT-062 V-4)
Brother (Family
UT-062 V-6)
Sister (Family
HU-314 IV-1)
— — Homozygous DGKE c.610ΔA
(p.T204Qframeshift210X)
Sister (Family
HU-314 IV-2)
— —
Sister (Family
HU-500 V-1)
C3 neg; IgM, IgG
pos
— Homozygous DGKE c.889–2 (p.W350X)
Twin brother (Family
HU-500 V-2)
— — —
Twin brother (Family
HU-500 V-3)
— — —
Tortajada
et al. (2013)
[5]
C3 glomerulopathy Son (GN29) Diffuse C3,
mesangial IgM; IgG
neg
Within GBM and
mesangium
Slightly
low
Neg Normal CFHR112341–5 Heterozygous internal
duplication of exons
2–5 (SCRs 1–4) of
CFHR1Mother (GN29 M) Diffuse C3; IgG/
IgM neg
Subendothelial,
subepithelial, mesangial
(with absent
CFHR1, 3)
(with
homozygous
ΔCFHR3/1)
DDD Maternal grandfather
(GN29GF)
— — — — — — —
Continued
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Chen et al. reported a UK sibship with C3 glomerulopathy
associated with heterozygous deletion of exons 4–5 of CFHR2
[7]. This produced a hybrid protein consisting of SCR
domains 1 and 2 of CFHR2 linked to full-length CFHR5
(CFHR212–CFHR51–9). Due to the similarity between the
initial two SCR domains of CFHR2 and CFHR5, the hybrid
CFHR212–CFHR51–9 protein is structurally similar to
CFHR5121–9.
A number of earlier family studies in which C3 glomerulo-
pathy was associated with mutations causing severe deﬁciency
or dysfunction of CFH have been summarized previously [9].
Recently, Wong et al. demonstrated association of a heterozy-
gous CFH non-synonymous coding variant (c.249G>T) with
MPGN in a UK family [8]. This mutation resulted in a serine
to arginine substitution (p.R83S) within SCR2. A recombinant
mutant CFH protein fragment (SCR domains 1–4) displayed
reduced C3b-binding and complement regulatory activity
in vitro compared with a recombinant wild-type CFH protein.
Ozaltin et al. identiﬁed a homozygous coding variant
(c.127C>T) in the diacylglycerol kinase ε (DGKε) gene in a
consanguineous Turkish family (denoted in the manuscript as
UT-062) with familial renal disease with features of MPGN
and thrombotic microangiopathy [4]. DGKε is an intracellular
lipid kinase that is expressed in podocytes. The coding variant
produces a premature stop codon (p.Q43X) leading to a trun-
cated protein. How this results in renal disease remains
unclear. However, the disease association was strengthened by
the identiﬁcation of other homozygous DGKE variants leading
to protein truncation in two other consanguineous families.
RECENT INSIGHTS INTO CFHR BIOLOGY
A key insight into the biology of CFHR1, CFHR2 and CFHR5
derived from the observation that a recombinant CFHR11–2
protein formed obligatory head-to-tail dimers via a unique
dimerization motif located within the highly conserved
N-terminal SCR domains 1 and 2 of CFHR1, -2 and -5 [10].
Recombinant CFHR5 was shown to be an exclusively dimeric
protein and, when key amino acids within the putative dimer-
ization domains were mutated, the recombinant protein was
monomeric. The identiﬁcation of the dimerization motif within
CFHR1, -2 and -5 leads to the prediction that both homo- and
heterodimers could exist between these proteins (Figure 3). Fur-
thermore, a common structural polymorphism that results in
combined deletion of the CFHR1 and CFHR3 genes (ΔCFHR3/
1) would result in deﬁciency of not only the CFHR1 homodi-
mer but also deﬁciency of heterodimers containing CHFR1
(CFHR1–CFHR2 and CFHR1–CFHR5 heterodimers).
What is the relevance of these observations to patients with
familial C3 glomerulopathy associated with abnormal CFHR
proteins? Duplication of the dimerization motif and the pres-
ence or absence of the ΔCFHR3/1 allele could theoretically
lead to diverse species of CFHR homo- and heterodimers
(Table 2). Deﬁning the composition of these proteins in vivo is
a prerequisite to understanding the association of abnormal
CFHR proteins with C3 glomerulopathy. In addition, it is im-
portant for our understanding of why the ΔCFHR3/1 alleleTa
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modiﬁes disease susceptibility in age-related macular degener-
ation [11], systemic lupus erythematosus [12] and IgA nephro-
pathy [13].
At present, there is strong evidence to support the existence
of all three homodimers [5, 10] but only one heterodimer
(CFHR1–CFHR2). The latter was readily identiﬁed because
CFHR1 but not CFHR2 interacts with heparin. When serum
or plasma is subjected to heparin chromatography, CFHR2 is
only retained (bound to heparin) in the presence of CFHR1
[5, 10]. The CFHR1–CFHR5 heterodimer has less clearly been
identiﬁed [5, 10] while CFHR2–CFHR5 was not seen in one
study [5] or was seen only in very low amounts in another
[10]. In addition to dimerization, there is evidence that these
proteins can form larger complexes [5]. Following heparin
chromatography of CFHR1-containing plasma, protein
complexes of various sizes were identiﬁed, consistent with for-
mation of CFHR1 homo-oligomers and a variety of CFHR1–
CFHR2 and CFHR1–CFHR5 hetero-oligomers [5].
What is the functional signiﬁcance of dimerization and/or
oligomerization? One obvious consequence would be an in-
crease in avidity. Compared with monomeric recombinant
CFHR5 (lacking the dimerization motif), dimeric recombinant
CFHR5 displayed increased binding to GBM-bound mouse C3
in vivo in the Cfh-deﬁcient mouse model of C3 glomerulopathy
[10]. Monomeric proteins also interacted less effectively than
dimeric proteins with human C3b in vitro [5, 10]. The signiﬁ-
cance of this increased avidity became clearer when it was pro-
posed that following binding to C3b, unlike CFH, CFHR1, -2
and -5 do not inhibit C3b ampliﬁcation but actually allow it to
proceed [5, 10]. This led to the hypothesis that CFHR proteins,
by competing with CFH for surface C3b, could inﬂuence the
degree to which C3b ampliﬁcation is inhibited (predominant
CFH binding) or allowed to proceed (predominant CFHR
binding). The latter process was termed CFH de-regulation
since these CFHR proteins were devoid of any intrinsic comple-
ment regulatory activity.
F IGURE 3 : Schematic representation of potential homodimers and heterodimers within the CFHR1, CFHR2 and CFHR5 protein family. The
dimerization motif is located within N-terminal SCR domains 1 and 2 of CFHR1, -2 and -5 (depicted in blue) enabling head-to-tail dimer for-
mation. Potential homo- and heterodimers are shown. The combined deletion of the CFHR1 and CFHR3 genes (ΔCFHR3/1) would, in homozy-
gosity, result in a complete loss of CHFR1-containing species. In this setting, the potential species comprise: CFHR2 and CFHR5 homodimers
and a CFHR2–CFHR5 heterodimer (inset).
Table 2. Predicted homodimers and heterodimers associated with abnormal CFHR proteins in patients with C3 glomerulopathy
Modiﬁed CFHR protein Abnormal homodimers Abnormal heterodimers
CFHR1, CFHR3 present Homozygous ΔCFHR3/1
CFHR112341–5 (CFHR112341–5) × 2 (CFHR112341–5)–CFHR1
(CFHR112341–5)–CFHR2
(CFHR112341–5)–CFHR5
CFHR112341–5)–CFHR2
(CFHR112341–5)–CFHR5
CFHR5121–9 (CFHR5121–9) × 2 (CFHR5121–9)–CFHR1
(CFHR5121–9)–CFHR2
(CFHR5121–9)–CFHR5
(CFHR5121–9)–CFHR2
(CFHR5121–9)–CFHR5
CFHR212–CFHR5 (CFHR212–CFHR5) × 2 (CFHR212–CFHR5)–CFHR1
(CFHR212–CFHR5)–CFHR2
(CFHR212–CFHR5)–CFHR5
(CFHR212–CFHR5)–CFHR2
(CFHR212–CFHR5)–CFHR5
CFHR312–CFHR1 (CFHR312–CFHR1) × 2 (CFHR312–CFHR1)–CFHR1
(CFHR312–CFHR1)–CFHR2
(CFHR312–CFHR1)–CFHR5
(CFHR312–CFHR1)–CFHR2
(CFHR312–CFHR1)–CFHR5
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CFH de-regulation has been shown in vitro. Normal CFHR
proteins (CFHR1, -2 and -5) can compete with CFH for
binding to shared surface ligands in vitro using heterolo-
gous erythrocytes (guinea-pig erythrocytes) as a complement-
activating surface [5, 10]. By increasing the CFHR protein
concentration, the interaction between CFH and surface
ligands can be inhibited, resulting in lysis of the guinea pig er-
ythrocytes. Notably, monomeric forms of these CFHR pro-
teins were less efﬁcient at CFH de-regulation than dimeric
forms, presumably due to differences in avidity [5, 10]. Abnor-
mal CFHR proteins are even more efﬁcient de-regulators of
CFH in this assay. Serum fractions, containing all CFHR1, -2
and -5 species from individuals with C3 glomerulopathy asso-
ciated with either the CFHR5121–9 or CFHR312–CFHR1 ab-
normal protein, demonstrated enhanced red cell lysis
(consistent with greater CFH de-regulation) [10]. Similarly, a
CFHR1-containing protein preparation from a family member
with the CFHR112341–5 protein (and accompanying homozy-
gous ΔCFHR3/1) also mediated enhanced lysis of guinea-pig
erythrocytes [5]. This patient preparation was then enriched
for large multimeric complexes, which could be visualized
using electron microscopy as ‘bundle-like structures’ (whereas
puriﬁed normal CFHR1 and CFH could not be seen).
However, antagonism of CFH by normal or abnormal CFHR
proteins has not been demonstrated in vivo or on GBM pre-
parations. In addition, the physiological relevance of CFH de-
regulation by normal CFHR proteins remains unknown. An
important and interesting observation indicating that our
knowledge in this area remains incomplete is that the hybrid
CFHR212–CFHR5 protein [7], unlike the structurally very
similar CFHR5121–9, protein [2], was associated with severe
plasma C3 depletion. Recombinant CFHR212–CFHR5 protein
enhanced the formation of the AP C3 convertase in the
absence of CFH and inhibited its dissociation in the presence
of CFH. This activity is similar to C3 nephritic factor and may
be the reason that the phenotype was associated with very low
plasma C3 levels.
TOWARDS A DISEASE MECHANISM
A number of processes by which C3 fragments accumulate
along the GBM in C3 glomerulopathy can now be proposed
(Figure 4). Under physiological conditions, C3b ampliﬁcation is
limited by the actions of CFH. It has been difﬁcult to establish
whether CFH prevents C3 accumulation along the GBM pri-
marily by regulating the AP in the circulation, or by ﬁrst attach-
ing to the GBM in order to mediate its protective effects. Most
likely, CFH performs both these actions in response to the
various exogenous triggers of C3 activation encountered by the
innate immune system (e.g. infection). In patients with abnor-
mal CFH, the physiological mechanism of ‘C3 tickover’,
whereby spontaneous C3 activation occurs via the AP in the cir-
culation, proceeds without inhibition. This results in severe sec-
ondary consumption of plasma C3 and the AP activation
protein, factor B, even in the absence of any exogenous trigger
of C3 activation. Experimentally, accumulation of C3 fragments
along the GBM has been demonstrated only in the setting of
uncontrolled C3 activation due to complete CFH deﬁciency. In-
dividuals with complete CFH deﬁciency and C3 glomerulopa-
thy typically have very low plasma C3 levels in addition to
abnormal glomerular C3 accumulation. In contrast, patients
with C3 glomerulopathy associated with abnormal CFHR pro-
teins but intact CFH often [2, 6], but not invariably [7], have
normal or only moderately reduced plasma C3 levels. One ex-
planation for the association between familial C3 glomerulopa-
thy and abnormal CFHR proteins is that these interfere with the
CFH regulation of C3 activation predominantly along the
GBM. This would result in abnormal glomerular C3 deposition
with less marked or no effect on plasma C3 regulation. Hence
the CFHR212–CFHR5 [7] protein may interfere with CFH regu-
lation of C3 both along the GBM (resulting in C3 glomerulopa-
thy) and in the circulation (resulting in plasma C3 depletion).
THE CURRENT HISTOPATHOLOGICAL
DEFINITION OF C3 GLOMERULOPATHY
Hou et al. conducted a review of 319 biopsies showing MPGN,
in which different cut-off levels for glomerular immunoglobu-
lin (Ig) deposition were evaluated as part of immunoﬂuores-
cence criteria for diagnosis of C3 glomerulopathy [14]. The
results (published simultaneously with the consensus report)
showed that strict deﬁnition of C3 glomerulopathy based on
‘C3 only’ (i.e. total absence of glomerular Ig) was impractical,
since it excluded half of the 42 DDD cases identiﬁed on EM.
Instead, a more inclusive criterion of predominant glomerular
C3 intensity of ≥2 levels of magnitude greater than any com-
bination of IgG, IgM, IgA and C1q increased the sensitivity for
DDD to 88%. Applying this criterion to 200 cases previously
diagnosed as MPGN Type 1, and 77 cases of MPGN Type 3,
in which secondary causes including hepatitis C infection,
cryoglobulinaemia and paraproteinaemia had been excluded,
31% and 39%, respectively, could be classiﬁed as C3 glomeru-
lopathy. The authors concluded that this approach identiﬁed
those patients who were most likely to beneﬁt from evaluation
of the AP. It is now recommended that in practice ‘glomerulo-
nephritis with dominant C3’ should be used as a morphologic-
al term for those cases with dominant staining for C3c.
Dominant is deﬁned as C3c intensity two orders of magnitude
more than any other immune reactant on a scale of 0–3 (com-
prising 0, trace, 1, 2 and 3). This approach will identify the ma-
jority of cases of C3 glomerulopathy and trgger (depending on
the clinical scenario) investigations to identify known comple-
ment abnormalities [1].
RECENT RETROSPECTIVE COHORT STUDIES
As C3 glomerulopathy is extremely rare, patient cohort studies
provide valuable information regarding clinical and patho-
logical features and their correlation with disease outcomes
[15]. Medjeral-Thomas et al. conducted a retrospective cohort
study in 80 adults and children in the UK and Ireland with C3
glomerulopathy [16]. Based on a strict deﬁnition of C3 glo-
merulopathy (in which cases were excluded if any amount of
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glomerular IgG/IgA or more than weak IgM was demonstrated
on immunostaining), they estimated an annual incidence of
one to two cases per million population. Electron microscopy
was performed in all cases, enabling a number of important
clinicopathologic distinctions to be drawn between DDD (21
patients) and C3GN (59 patients). Age at diagnosis was signiﬁ-
cantly lower for DDD (median age 12 versus 26 for C3GN), and
low serum C3 levels at diagnosis signiﬁcantly more common
(79% versus 48% in C3GN among the 69 patients assessed).
MPGN was the most common lesion on light microscopy in
both groups (55% of all biopsies). Presence of >50% crescents
was more common in DDD (19% of biopsies versus 5% in
C3GN), whereas vascular disease and chronic changes including
glomerulosclerosis and interstitial ﬁbrosis were more common
in C3GN. At a median follow-up of 28 months, 29% of patients
had developed ESKD, with no difference in renal survival
between DDD and C3GN. However using multivariate analysis,
DDD emerged as a strong and independent predictor of ESKD,
along with age ≥16 years at diagnosis and crescentic GN. Histo-
logical recurrence following renal transplantation in all six DDD
recipients was associated with graft failure in three cases, while
four of seven C3GN recipients had histological recurrence, with
graft failure in three cases. Zand et al. reported a US retrospective
cohort of 21 adult and paediatric patients transplanted for ESKD
due to C3GN, of whom two-thirds had histological recurrence,
with half of these developing subsequent graft failure [17]. Re-
currence and graft failure rates have been similar in earlier
DDD/C3GN cohort studies, although it is unclear whether graft
F IGURE 4 : Schematic representation of pathogenesis of C3 glomerulopathy. Triggers of C3 activation (depicted at the centre) may be exogen-
ous (e.g. infection) or endogenous (C3 tickover). C3 activation generates C3b molecules for attachment to surfaces including the GBM. In health
(upper panel), C3b ampliﬁcation is tightly controlled by factor H (CFH) in the circulation. Thus minimal C3b becomes available for attachment
to surfaces, where ampliﬁcation is further regulated by CFH on the GBM. In theory, any surface-attached C3b is then metabolised, leaving C3
fragments (iC3b, C3d) attached to the GBM, and releasing CFH back into the circulation. In practice, neither C3 nor CFH are detected along the
GBM in normal glomeruli. In the setting of abnormal CFH (bottom left panel), uncontrolled C3 activation leads to excessive C3 fragments
(iC3b, C3d) in the circulation, which later accumulate along the GBM. Some C3b ampliﬁcation/metabolism may also occur on the GBM.
Enhanced CFH de-regulation due to abnormal CFHR proteins (bottom right panel) has been proposed as one mechanism by which C3
accumulates along the GBM despite intact CFH. Competitive inhibition of CFH by abnormal CFHR proteins along the GBM would facilitate
C3b surface ampliﬁcation/metabolism. Increased C3b ampliﬁcation in plasma due to an abnormal CFHR protein that stabilizes the C3
convertase has also been demonstrated (see the text).
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survival is reduced in recipients with C3 glomerulopathy com-
pared with other types of glomerulonephritis. Nevertheless,
development of effective therapies for use in native C3 glomeru-
lopathy may ultimately also be beneﬁcial in the transplant
setting.
RECENT TREATMENT STUDIES
As no treatment is proven to be beneﬁcial for C3 glomerulopa-
thy, research interest in therapeutic agents that modulate the
complement pathways is high. Eculizumab is a humanized
anti-complement C5 monoclonal antibody approved for use
in patients with paroxysmal nocturnal haemoglobinuria and
aHUS. Off-label use of eculizumab for treatment of C3 glo-
merulopathy was initially reported in three cases of DDD
[18, 19] (one with transplant recurrence [21]) and an addition-
al case of MPGN Type 1 [20]. In 2012, a prospective trial was
reported by Bomback et al. in six patients with native or post-
transplant recurrent DDD or C3GN [22]. Since the trial, at
least seven additional case reports of eculizumab use in C3 glo-
merulopathy have been published, most involving patients
with persistent disease despite immunosuppressive therapy
(Table 3). In the trial, eculizumab therapy was associated with
a signiﬁcant fall in serum creatinine or proteinuria in only 3
out of 6 patients, whereas 9 out of the total 11 case reports
showed clinical improvement, raising the possibility of publi-
cation bias. Nevertheless, further prospective evaluation of
eculizumab in C3 glomerulopathy appears warranted, with ju-
dicious patient selection based on available prognostic data
from retrospective cohort studies and the like. Information
obtained from renal biopsy both before and after treatment,
for example the degree of active inﬂammation, may ultimately
also guide eculizumab use, although evidence for this approach
from the existing studies is limited [19, 23, 29, 30]. It has not
been established whether disease progression occurs in some
cases despite therapeutic blockade of C5 activation, as a result
of ongoing upstream activation of C3. This concept was
highlighted by the family study involving CFHR212–CFHR5,
in which eculizumab was associated in vitro with effective
blockade of C5 activation but not C3 activation in patient
serum [7]. A Phase 1 clinical trial in children and adults with
DDD (NCT01791686) is currently evaluating recombinant
soluble complement receptor 1 (CR1), which was previously
shown to restore plasma C3 levels and reduce glomerular C3 in
Cfh−/− mice [31], and inhibited C3 activation in vitro in the
CFHR212–CFHR5 family study [7]. Elsewhere rituximab has
been reported with success in individual cases of C3 glomerulo-
pathy [17, 32] (as distinct from rituximab use in treatment
of disease-associated paraproteinaemia). However treatment
failure following sporadic use of rituximab, often in conjunction
with immunosuppressive treatment (including in the renal
transplant setting), has also been widely reported [17, 18, 21, 23,
26, 28, 29].
CONCLUSION
Enhanced CFH de-regulation has been proposed as a distinct
pathophysiological mechanism in several families in which C3
glomerulopathy segregates with mutations leading to abnor-
mal CFHR proteins. These abnormal proteins display in-
creased avidity for C3b and an enhanced ability to antagonize
CFH in vitro. Hence, in patients with C3 glomerulopathy, ab-
normal CFHR proteins seem likely to prevent CFH-mediated
inhibition of C3b ampliﬁcation along the GBM. In patients
with CFH deﬁciency/dysfunction, excessive production of C3
fragments in the circulation, which then accumulate within
the kidney, provides an additional disease mechanism for C3
glomerulopathy. We now have an improved means of identify-
ing patients with C3 glomerulopathy through the introduction
of a renal biopsy classiﬁcation: glomerulonephritis with dom-
inant C3. As C5 inhibition is not effective in at least some pa-
tients, we need to look for new approaches, the most obvious
being to inhibit C3 activation. How this is achieved will
depend on how and where the defect in C3 regulation has
Table 3. Published reports of eculizumab use in C3 glomerulopathy and MPGN
Report (year) Study design Reported diagnosis (age at
treatment/sex)
C3NeF Treatment duration
(months)
Clinical
response
Daina et al. (2012) [18] Case report DDD (22F) + 11 Yes
Vivarelli et al. (2012) [19] Case report DDD (17M) + 18 + 9 Yes
Radhakrishnan et al. (2012) [20] Case report MPGN Type 1 (16F) + 1.5 Yes
McCaughan et al. (2012) [21] Case report Allograft recurrent DDD (29F) + 2.5 Yes
Bomback et al. (2012) [22] Prospective, open-label,
uncontrolled trial
DDD (22M) − 12 Yes
50% 82%
DDD (42M) + 9 No
Allograft recurrent DDD (32M) − 12 Yes
C3GN (25M) − 12 No
Allograft recurrent C3GN (22M) + 12 No
Allograft recurrent C3GN (20M) + 12 Yes
Gurkan et al. (2013) [23] Case report Allograft recurrent C3GN (21M) + 12 Yes
Besbas et al. (2013) [24] Case report C3 glomerulopathy (16F) − 10 No
Kerns et al. (2013) [25] Case report C3 glomerulopathy (16M) − 3.5 Yes
Rousset-Rouvière et al. (2014) [26] Case report DDD (10M) + 6.5 Yes
Ozkaya (2014) et al. [27] Case report DDD (14F) + 7 Yes
Berthe-Aucejo et al. (2014) [28] Case report DDD (17M) + 3.5 No
Sánchez-Moreno et al. (2014) [29] Case report Allograft recurrent DDD (14F) + 30 Yes
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arisen. In addition, we need continued clinicopathological
phenotyping, a prerequisite to the design of informative clinic-
al trials. There are many ongoing innovative approaches to
these challenges so the future for patients with C3 glomerulo-
pathy is bright.
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